HTAi
HEALTH
TECHNOLOGY
ASSESSMENT
iNTERNATIONAL

WS04 - Bridging Health Technology Assessment Results With Payment Models For Cell And Gene Therapies

Facilitators

Antal Zemplenyi, Brett McQueen, Woojung Lee

Summary

This workshop teaches participants how to translate key findings from health technology assessments into outcomes-based agreements for cell and gene therapies. Using real-world examples and interactive exercises, attendees will learn to identify uncertainty types, design appropriate contract scenarios, and support these with cost-offset modeling to assess financial impact. Ideal for HTA professionals, payers, manufacturers, and policy decision-makers.

Outcomes and Objectives

Participants will (i) learn how to identify the key data and analyses required to structure outcomes-based contracts for CGTs, (ii) understand how real-world cost drivers and eligibility scenarios influence the design of OBAs, and (iii) assess OBA feasibility given uncertainties identified in HTAs. This workshop will provide a generalizable framework for linking types of uncertainty to payment model features and will equip attendees with practical tools for simulating OBA impacts using real-world data relevant to payers.

Structure of Session

We will begin by assessing participants' understanding of the gap between HTA findings and payment design. Dr. Zemplenyi will present real-world examples from U.S. HTA, such as hemophilia and sickle-cell disease, to illustrate cost-offset modeling and payment simulations. Dr. McQueen will lead active exercises to specify costs, model the financial impact of OBAs, define scenarios, and translate these into contract terms. The session will conclude with Dr. Lee presenting ICER’s qualitative and quantitative approaches to linking HTA uncertainty to OBAs.